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 Background: Alteration of DNA methylation of tumor suppressor genes (TSGs) is one of the most consistent epigenetic 
changes in human cancers. DNMTs play several important roles in DNA methylation and development of can-
cers. Regarding DNMTs protein expressions, little is known about the clinical significance and correlation with 
promoter methylation status of TSGs in human pituitary adenomas.
 Material/Methods: We analyzed the protein expression of 3 DNMTs using immunohistochemistry and assessed DNA hypermeth-
ylation of RASSF1A, CDH13, CDH1, and CDKN2A (p16) in 63 pituitary adenomas. We examined associations be-
tween DNMTs expression and clinicopathological features or promoter methylation status of TSGs.
 Results: Overexpression of DNMTs was detected in pituitary adenomas. Frequencies of DNMT1 overexpression were 
significantly higher in macroadenomas, invasive tumors, and grade III and IV tumors. DNMT3A was frequently 
detected in invasive tumors and grade IV tumors. In addition, DNMT1 and DNMT3A were frequently detected 
in high-methylation tumors. Furthermore, in multivariate logistic regression, the significant association between 
DNMT1 or DNMT3A and high-methylation status persisted after adjusting for clinicopathological features.
 Conclusions: Our findings suggested that tumor overexpression of DNMT1 and DNMT3A is associated with tumor aggres-
sive behavior and high-methylation status in pituitary adenomas. Our data support a possible role of DNMT1 
and DNMT3A in TSG promoter methylation leading to pituitary adenoma invasion and suggest that inhibition 
of DNMTs has the potential to become a new therapeutic approach for invasive pituitary adenoma.
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 Abbreviations: ACTH – corticotroph adenoma; ACTHs – silent corticotroph adenoma; DNMT – DNA methyltransferase; 
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ma; MSP – methylation-specific PCR; PRL – lactotroph adenoma; Null cell – null cell adenoma; 
TSH – TSH cell adenoma; Silent subtype 3 – silent subtype 3 adenoma; TSG – tumor suppressor gene
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Background
Pituitary adenoma is a common tumor of the skull base and 
is also known as pituitary adenoma. It is a common neuro-
endocrine tumor and accounts for about 10–15% of central 
nervous system tumors [1]. They can cause mood disorders, 
sexual dysfunction, infertility, obesity, visual disturbances, 
hypertension, diabetes mellitus, and accelerated heart dis-
ease [2–4]. However, the treatment of pituitary adenoma has 
been a challenge in neurosurgery. Only by deeply studying its 
molecular mechanism and developing targeted drugs can the 
tumor be completely cured. Abnormal regulation of epigenetics 
is an important mechanism leading to the occurrence of can-
cer and DNA methylation is the most common phenomenon 
in epigenetics. About 80% of CpG sites in the human genome 
undergo methylation changes and 70% of sites are methylat-
ed at certain times, indicating that methylation regulation of 
the whole genome is common [2]. While genetic events are 
rarely involved in pituitary tumorigenesis, inactivation of sev-
eral tumor suppressor genes (TSGs) and DNA repair genes by 
DNA hypermethylation has been reported in pituitary ade-
nomas [5–14]. These finding suggest that the down-regulat-
ed expression of TSGs by DNA hypermethylation is an impor-
tant mechanism contributing to pituitary tumorigenesis [2,15].
Among the CpG methylation enzymes associated with gene si-
lencing, 3 functional DNA methyltransferases (DNMTs) – DNMT1, 
DNMT2, and DNMT3 – have distinctive roles [16–19]. DNMT1 
is known to maintain methylation [20], no transmethylase ac-
tivity has been found with DNMT2, and the DNMT3 family con-
sists of 2 related gene product – DNMT3A and DNMT3B – which 
function as de novo methylation activity (based upon plasmid 
methylation) [5]. Studies have found that DNMT1, DNMT3A, and 
DNMT3B are overexpressed in a variety of cancers and result in 
poor histological differentiation and poor prognosis [21–27]. In 
addition, drugs that inhibit the reversal of abnormal DNA meth-
ylation patterns by DNMTs have been widely studied in cancer 
treatment, and the specificity and efficacy of these drugs have 
been confirmed in experimental and clinical trials [28–31]. The 
function of DNMTs, which mediate epigenetic control, has been 
identified in human and mouse pituitary tumors [19,32,33]. 
However, DNMT1, DNMT3A, and DNMT3B protein expression has 
not been comprehensively studied in sporadic human pituitary 
adenomas. Their clinical relevance and association with promot-
er methylation of TSGs in pituitary adenomas remain unknown.
In the present study, we used immunohistochemical methods 
to detect the expression of DNMT1, DNMT3A, and DNMT3B 
proteins and promoter methylation of 4 TSGs by methylation-
specific PCR (MSP) in 63 pituitary adenomas. We analyzed the 
associations between the expression of DNMT1, DNMT3A, or 
DNMT3B proteins and clinicopathologic features and promot-
er methylation status of TSGs.
Material and Methods
Human normal and pituitary adenoma samples
Informed consent was obtained from all subjects involved in the 
study, and the study was approved by the Ethics Committees 
of The University of Tokushima and Toranomon Hospital.
Five normal human adenohypophyses were obtained at autop-
sy from patients with no evidence of endocrine abnormality; 
they were examined histologically and immunocytochemical-
ly to exclude the possibility of incidental pathology. We ob-
tained 63 tissue specimens from patients with pituitary adeno-
ma who underwent surgery at Tokushima University Hospital 
(Tokushima, Japan) or Toranomon Hospital (Tokyo, Japan). 
Pituitary tumor tissue was fresh-frozen with liquid nitrogen 
and stored at –80°C for DNA and RNA extraction. Tumors en-
rolled in this study were characterized according to clinical, 
radiological, histological, and immunohistochemical features 
(Table 1). They were divided into functional and non-function-
al categories according to the secretion hormone of pituitary 
adenoma. Clinically functional tumors comprised 24 somato-
troph adenomas, 2 mammosomatotroph adenomas, 10 lac-
totroph adenomas, and 4 corticotroph adenomas associated 
with Cushing’s disease. Clinically non-functioning adenomas 
comprised 5 silent corticotroph adenomas, 12 gonadotroph 
adenomas, 3 silent subtype 3 adenomas, and 1 null cell ad-
enoma characterized by immunoreactivity for all anterior pi-
tuitary hormones. The size and invasiveness of tumors were 
defined based on preoperative radiological examination, sur-
gical results, and modified Hardy classification. Grade I (diam-
eter of microadenoma <1 cm) and grade II (diameter of en-
closed microadenomas with or without suprasellar extension 
³1 cm) tumors were defined as non-invasive. Grade III (local 
invasion of sphenoid and/or cavernous sinus) and grade IV 
(central nervous system/extracranial spread with or without 
metastasis) tumors were considered to be invasive. Thus, the 
63 included tumors (30 non-invasive and 33 invasive adeno-
mas) comprised 9 grade I tumors, 21 grade II tumors, 25 grade 
III tumors, and 8 grade IV tumors (Table 1). There was no ev-
idence of recurrence of any tumor in this study. Hematoxylin 
and eosin-stained tissue sections from all 63 pituitary adeno-
mas were reviewed and confirmed by 2 pathologists (Toshiaki 
Sano and ZRQ).
Immunohistochemistry
Immunolocalization of DNMT1, DNMT3A, DNMT3B, and MKI67 
(Ki-67) antigen based on the streptavidin-biotin labeling meth-
od was performed on sections from representative blocks of 
paraffin-embedded tissues used for pathology diagnosis. After 
deparaffinization and antigen retrieval using an autoclave oven 
technique, the sections were incubated at 4°C overnight with 
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antibodies: goat polyclonal anti-DNMT1 (1: 100; Santa Cruz 
Biotech, Santa Cruz, CA), goat polyclonal anti-DNMT3a (1: 150; 
Santa Cruz Biotech), goat polyclonal anti-DNMT3b (1: 100; 
Santa Cruz Biotech), or with MIB-1 mouse monoclonal antibody 
(1: 100, DakoCytomatin, Glostrup, Denmark). Antigen-antibody 
complexes were detected using the 3-amino-9- ethylcarba-
zole reaction. After immunohistochemical staining, the slides 
were observed and analyzed by an electron microscope. Colon 
and breast cancer samples known to be positive for DNMT1, 
DNMT3A, and DNMT3B were used as positive controls [21,24]. 
Variables No.
DNMT1 DNMT3A DNMT3B
+ – P + – P + – P
Total 63 21 42 23 40 20 43
Gender 0.72 0.41 0.33
 Female 34 12 22 14 20 9 25
 Male 29 9 20 9 20 11 18
Mean age (yrs) ±SD 47±16 47±16 47±16 0.95 45±15 48±17 0.55 49±14 46±17 0.52
Tumor type 0.22 0.68 0.59
 GH (acromegaly) 24 6 18 6 18 9 15
 GH/PRL (acromegaly) 2 0 2 1 1 0 2
 PRL (prolactinoma) 10 2 8 5 5 5 5
 TSH 2 2 0 1 1 0 2
 ACTH (Cushing) 4 1 3 1 3 0 4
 ACTH (silent) 5 3 2 3 2 2 3
 FSH/LH (NF) 12 5 7 4 8 3 9
 Null cell (NF) 1 1 0 1 0 0 1
 Silent subtype 3 3 1 2 1 2 1 2
Tumor size 0.02 0.08 0.38
 Micro-adenoma 9 0 9 1 8 4 5
 Macro-adenoma 54 21 33 22 32 16 38
Invasion 0.03 0.03 0.42
 Non-invasive 30 6 24 7 23 8 22
 Invasive 33 15 18 16 17 12 21
Grade
 I 9 0 9 1 8 4 5
 II 21 6 15 0.07 6 15 0.30 4 17 0.14
 III 25 9 16 0.03 11 14 0.07 10 15 0.81
 IV 8 6 2 0.001 5 3 0.02 2 6 0.40
Table 1. Clinicopathologic characteristics in pituitary adenomas.
ACTH – corticotroph adenoma; ACTHs – silent corticotroph adenoma; FSH/LH – gonadotroph adenoma; GH – somatotroph adenoma; 
GH/PRL – mammosomatotroph adenoma; PRL – lactotroph adenoma; Null cell – null cell adenoma; TSH – TSH cell adenoma; Silent 
subtype 3 – silent subtype 3 adenoma; M – methylated; UM – unmethylated; SD – standard deviation. The chi-square test was used 
to analyze the differences in frequencies of DNMTs immunoreaction and promoter methylation of TSGs among each group of pituitary 
adenomas.
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Nuclear immunoreactivity in the proliferative zones of noncan-
cerous foveolar epithelia was used as a positive control for 
some sections. The sections were incubated with phosphate 
buffer solution without the primary antibody as a negative con-
trol. Furthermore, the specificity of all reactions for DNMT1, 
DNMT3A, and DNMT3B was verified by replacing the primary 
antibody with normal serum and pre-absorbing each prima-
ry antibody with blocking peptide (Santa Cruz Biotech). Each 
section was examined independently by 2 investigators in a 
blinded manner. Nuclear staining was considered to represent 
Variables No.
RASSF1A CDH13 CDH1 CDKN2A (P16)
M UM P M UM P M UM P M UM P
Total 63 23 40 20 43 24 39 32 31
Gender 0.17 0.23 0.30 0.52
 Female 34 15 19 13 21 11 23 16 18
 Male 29 8 21 7 22 13 16 16 13
Mean age (yrs) ±SD 47±16 49±18 46±15 0.48 45±16 48±16 0.54 48±18 46±15 0.73 48±16 46±17 0.68
Tumor type 0.49 0.85 0.08 0.23
 GH (acromegaly) 24 11 13 6 18 5 19 16 8
 GH/PRL (acromegaly) 2 0 2 1 1 0 2 1 1
 PRL (prolactinoma) 10 4 6 4 6 5 5 3 7
 TSH 2 0 2 1 1 2 0 2 0
 ACTH (Cushing) 4 2 2 1 3 1 3 1 3
 ACTH (silent) 5 2 3 2 3 1 4 1 4
 FSH/LH (NF) 12 2 10 3 9 7 5 6 6
 Null cell (NF) 1 0 1 1 0 1 0 1 0
 Silent subtype 3 3 2 1 1 2 2 1 1 2
Tumor size 0.59 0.15 0.07 0.3
 Micro-adenoma 9 4 5 1 8 1 8 6 3
 Macro-adenoma 54 19 35 19 35 23 31 26 28
Invasion 0.90 0.01 0.45 0.16
 Non-invasive 30 11 19 5 25 10 20 18 12
 Invasive 33 12 21 15 18 14 19 14 19
Grade
 I 9 4 5 1 8 1 8 6 3
 II 21 7 14 0.56 4 17 0.59 9 12 0.09 12 9 0.62
 III 25 6 19 0.24 10 15 0.11 9 16 0.16 11 14 0.24
 IV 8 6 2 0.20 5 3 0.02 5 3 0.02 3 5 0.22
Table 2. Clinicopathologic characteristics in pituitary adenomas.
ACTH – corticotroph adenoma; ACTHs – silent corticotroph adenoma; FSH/LH – gonadotroph adenoma; GH – somatotroph adenoma; 
GH/PRL – mammosomatotroph adenoma; PRL – lactotroph adenoma; Null cell – null cell adenoma; TSH – TSH cell adenoma; Silent 
subtype 3 – silent subtype 3 adenoma; M – methylated; UM – unmethylated; SD – standard deviation. The chi-square test was used 
to analyze the differences in frequencies of DNMTs immunoreaction and promoter methylation of TSGs among each group of pituitary 
adenomas.
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a positive stain for DNMT1, DNMT3A, DNMT3B, and MKI67. A 
total of 1000 cells were counted at several high-power fields 
(×200) selected from different staining density regions, in-
cluding high-, moderate-, low-, and negative-staining areas. 
In a few samples with small size, there were fewer than 1000 
counted cells. DNMT1, DNMT3A, and DNMT3B positivity (i.e., 
overexpression) was defined as ³10% of tumor cells with nu-
clear staining. DNMTs 2 was defined as the presence of ³2/3 
DNMTs, DNMTs 1 as 1/3, and DNMTs 0 as 0/3 DNMTs.
Methylation analyses for TSG CpG islands
Genomic DNA was extracted from fresh-frozen tissue sam-
ples using the Qiagen DNeasy Tissue Kit (Qiagen, Stanford, 
CA) according to the manufacturer’s instructions. Genomic 
DNA was modified with sodium bisulfite and the modified ge-
nome DNA was purified by CpGenome DNA Modification Kit 
(Intergen, Purchase, NY),
Subsequently, the DNA promoter methylation status of the 
RASSF1A, CDH13, CDH1, and CDKN2A (P16) genes were in-
vestigated by MSP assay, as described previously [6]. The ap-
plication of specific primers and annealing temperatures for 
methylated and unmethylated promoters were described in 
previous reports [6,10,11]. CpG universally methylated hu-
man DNA (Intergen, Purchase, NY) was used as positive con-
trol, while distilled water served as the negative control, ac-
companied by every amplification reaction. PCR products were 
separated by electrophoresis in 2% agarose gel or nondena-
turing 6% polyacrylamide gel and were stained with ethidium 
bromide. To confirm the methylation state, the bisulfite reac-
tion and MSP of all samples were repeated. Methylated and 
unmethylated PCR products randomly selected and purified 
from the gels were processed to the direct sequencing analy-
sis using the NucleoSpin® Extract Kit (Macherey-Nagel, Düren, 
Germany). Cycle sequencing was performed using the BigDye 
Terminator V1.1 Cycle sequencing kit (Applied Biosystems) and 
was subsequently analyzed with the ABI PRISM 310 Genetic 
Analyzer (Applied Biosystems).
High-methylation status was defined as the presence of ³2/4 
methylated promoters of TSGs, and low-methylation/0 as 
0/4–1/4 methylated promoters of TSGs, according to previ-
ously established criteria [34].
Statistical analysis
SAS software (version 9.1; SAS Institute, Inc, Cary, NC) was 
used for all statistical analyses. For categorical data, the chi-
square test was performed. Probability (P) values were cal-
culated by ANOVA (analysis of variance) for age (Tables 1, 2). 
To assess independent effects of tumoral DNMT1, DNMT3A, 
and DNMT3B expression on tumoral methylation status, mul-
tivariate logistic regression analysis was done (with DNMT1, 
DNMT3A, and DNMT3B as an exposure of interest and high-
methylation status as an outcome variable) and odds ratio 
(OR) was adjusted for age (as a continuous variable), sex, and 
tumor grade (I–II vs. III–IV) (Table 3). P<0.05 were considered 
to be statistically significant.
Results
Expression analysis of DNMT1, DNMT3A, and DNMT3B in 
pituitary adenomas
In adenoma specimens, immunopositivity for DNMT1, DNMT3A, 
and DNMT3B showed a clear nuclear pattern. When present, 
this reactivity was typically very intense throughout the nuclei 
of tumor cells of various types (Figure 1A–1C). In addition, no 
or weak immunoreactivity for DNMT1, DNMT3A, and DNMT3B 
was observed in normal pituitary cells or non-neoplastic cells 
contained in surgical specimens.
Overexpression of DNMT1, DNMT3A, and DNMT3B was detect-
ed in 21 of 63 (33%), 20 of 63 (32%), and 23 of 63 (37%) ade-
nomas, respectively (Table 1). DNMT1, DNMT3A, and DNMT3B 
overexpression did not show any significant differences among 
subtypes of pituitary adenomas (Table 1). The overexpression 
of DNMT1 was more frequent (P<0.05, Table 1) in macroadeno-
mas (21/54, 39%) than in microadenomas (0/9, 0%). In addition, 
the overexpression of DNMT1 and DNMT3A was significantly 
more frequent in invasive adenomas (15/33, 45% and 16/33, 
48%) than in non-invasive adenomas (6/30, 20% and 7/30, 
Variable independently associated with methylation-high status* Multivariate OR (95% CI) P
DNMT1 + 3.63 (1.12–11.7) 0.031
DNMT3A + 3.38 (1.09–10.5) 0.035
Table 3.  Multivariate logistic regression analysis to assess relationship between expressions of DNMT1, DNMT3A and methylation-high 
status in pituitary adenomas.
Multivariate logistic regression analysis assessing the relationship of DNMT1 and DNMT3A expression with methylation-high status in 
pituitary adenomas initially included age, gender, tumor grade. * Tumor showed ³2 TSGs methylation. CI – confidence interval; 
OR – odds ratio.
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23%) (P=0.03 and P=0.03, respectively; Table 1). Furthermore, 
the overexpression of DNMT1 was more frequent in aggres-
sive grade IV (6/8, 75%) and grade III (9/16, 56%) cases com-
pared with grade I (0/9, 0%) cases (P=0.001 and P=0.03, re-
spectively; Table 1). The overexpression of DNMT3A was also 
more frequent in aggressive grade IV (5/8, 63%) cases com-
pared with grade I (1/8, 13%) cases (P=0.02; Table 1).
The overexpression of DNMT1, DNMT3A, and DNMT3B was 
not related to patient age, sex (Table 1), or proliferation mark-
er MKI67 labeling index (data not shown).
Promoter hypermethylation in RASSF1A, CDH13, CDH1, 
and CDKN2A (p16)
The promoter methylation of RASSF1A, CDH13, CDH1, and 
CDKN2A (p16) in 5 normal pituitary tissues and 63 pituitary ade-
nomas was investigated by MSP. The results are summarized in 
Table 2. Hypermethylation of the promoter region of RASSF1A, 
CDH13, CDH1, and CDKN2A (p16) was detected in 23 (37%), 
20 (32%), 24 (38%), and 32 (51%) pituitary adenomas, respec-
tively. However, there was no methylation of either promoter 
in 5 normal pituitary tissues. The results suggest that promot-
er hypermethylation of RASSF1A, CDH13, CDH1, and CDKN2A 
(p16) is tumor-specific. Methylated patterns of RASSF1A, CDH13, 
A B C
Figure 1.  Detection of immunostaining of DNMT1, DNMT3A, and DNMT3B in pituitary adenomas. Nuclear immunopositivities of 
DNMT1, DNMT3A, and DNMT3B were observed in tumor cells. The immunoreactivities of DNMT1, DNMT3A, and DNMT3B 
were variable but always very intense throughout the nuclei (positive cells are stained brown). (A) Strong nuclear DNMT1 
positivity, Original magnification, ×200. (B) Tumor with strong nuclear DNMT3A positivity, original magnification ×200. 
(C) tumor with strong nuclear DNMT3B positivity, original magnification ×400.
Figure 2.  The frequencies of TSG methylation status in adenomas according to expression of DNMT1, DNMT3A, and DNMT3B. 
(A) The groups with overexpression of DNMT1 and DNMT3A had more high-methylation tumors than the groups with low-
expression of DNMT1 and DNMT3A (72% vs. 40% and 69% vs. 40%, respectively). (B) The DNMTs 2 group had more high-
methylation tumors than DNMTs 1 and DNMTs 0 groups (76%, 35%, and 40%, respectively).
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CDH1, and CDKN2A (p16) did not show any significant differenc-
es among subtypes of pituitary adenomas (Table 2). The level of 
genomic DNA methylation was significantly different between 
invasive and non-invasive pituitary adenomas. We found that 
the methylation of CDH13 gene is more frequent in invasive 
pituitary adenomas than in non-invasive pituitary adenomas 
(5 of 30, 17%, P<0.05, Table 1). The methylation of CDH13 and 
CDH1 was more frequent in aggressive grade IV cases compared 
with grade I cases (P=0.02 and P=0.02, respectively, Table 2).
In addition, the specificity of MSP was confirmed by direct se-
quencing. In unmethylated MSP products, all cytosine nucleo-
tides, including those in the CpG islands, changed to thymidines 
as a result of bisulfite modification. However, in methylated 
MSP products, cytosine nucleotides in most CpG islands were 
unchanged (data not shown).
Association between tumoral DNMTs overexpression and 
TSG hypermethylation
High-methylation status was detected in 51% (32 of 63) of tu-
mors. DNMTs 2, DNMTs 1, and DNMTs 0 groups were found 
in 33% (21 of 63), 32% (20 of 63), and 35% (22 of 63) of tu-
mors, respectively.
We examined the frequencies of TSG high-methylation status 
in adenomas with overexpression of DNMT1, DNMT3A, and 
DNMT3B and in adenomas with underexpression of DNMT1, 
DNMT3A, and DNMT3B. The groups with overexpression of 
DNMT1 and DNMT3A included more high-methylation tumors 
than the groups with underexpression of DNMT1 and DNMT3A 
(72% vs. 40% and 69% vs. 40%, respectively, Figure 2A). In ad-
dition, high-methylation tumors showed higher frequencies of 
overexpression of DNMT1 and DNMT3A (43%, 15 of 32 and 
50%, 16 of 32, respectively) than in methylation-low tumors 
(19%, 6 of 32 and 22%, 7 of 32, respectively) (P=0.021 and 
P=0.023, respectively, Table 4). Furthermore, the DNMTs 2 
group had more high-methylation tumors than DNMTs 1 and 
DNMTs 0 groups (76%, 35%, and 40%, respectively, Figure 2B).
To confirm an independent relation between expression of 
DNMT1 and DNMT3A and high-methylation status, we per-
formed multivariate logistic regression analysis (Table 3). 
Overexpression of DNMT1 and DNMT3A was associated with 
Variable No.
DNMT1 DNMT3A DNMT3B
+ – P + – P + – P
Total  63  21 (33%)  42 (67%)  23 (38%)  40 (62%)  20 (32%)  43 (68%)
RASSF1A 0.45 0.82 0.86
 M  23 (38%)  9 (43%)  14 (33%)  8 (35%)  15 (38%)  7 (35%)  16 (37%)
 UM  40 (87%)  12 (57%)  28 (67%)  15 (65%)  25 (62%)  13 (65%)  27 (63%)
CDH13 0.18 0.001 0.83
 M  20 (32%)  9 (43%)  11 (26%)  13 (57%)  7 (18%)  6 (30%)  14 (33%)
 UM  43 (68%)  12 (57%)  31 (74%)  10 (43%)  33 (82%)  14 (70%)  29 (67%)
CDH1 0.09 0.08 0.83
 M  24 (38%)  11 (53%)  13 (31%)  12 (52%)  12 (30%)  8 (40%)  16 (37%)
 UM  39 (62%)  10 (47%)  29 (69%)  11 (48%)  28 (70%)  12 (60%)  27 (63%)
CDKN2A (P16) 0.85 0.16 0.93
 M  32 (51%)  11 (53%)  21 (50%)  9 (39%)  23 (58%)  10 (50%)  22 (51%)
 UM  31 (49%)  10 (47%)  21 (50%)  14 (61%)  17 (43%)  10 (50%)  21 (49%)
Methylation-high* 0.021 0.023 0.93
 +  32 (51%)  15 (71%)  17 (40%)  16 (70%)  16 (40%)  10 (50%)  22 (51%)
 –  31 (49%)  6 (29%)  25 (60%)  7 (30%)  24 (60%)  10 (50%)  21 (49%)
Table 4. Frequency of DNMT1, DNMT3A, and DNMT3B expression categorized by TSGs methylation status in pituitary adenomas.
* Tumor showed ³2 TSGs methylation. M, methylated; UM, unmethylated. The chi-square test was used to analyze the differences in 
frequencies of TSGs methylation status according to DNMTs immunoreaction.
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high-methylation status (multivariate OR, 3.63, 95% CI, 
1.12–11.7 and multivariate OR, 3.38, 95% CI, 1.09–10.5, re-
spectively) after adjusting for age, sex, and tumor grade.
The CDH13-methylated group included more DNMT3A-
overexpression tumors than the CDH13-unmethylated group 
(P=0.001, Table 4). However, there were no differential asso-
ciations between overexpression of DNMT1, DNMT3A, and 
DNMT3B and individual TSG methylation status (Table 4).
Discussion
Overexpression of DNMT1, DNMT3A, and DNMT3B has been 
reported in various cancers and is significantly correlated 
with poor prognosis [3,21–26]. In addition, hypermethylation 
of CpG islands results from up-regulation of DNMTs in hu-
man tumors [2]. In this study, we detected overexpression of 
DNMT proteins in pituitary adenomas. DNMT1 overexpres-
sion was associated with macroadenomas, invasive tumors, 
and grade III and IV tumors. In addition, DNMT3A overexpres-
sion was associated with invasive tumors and grade IV tumors. 
Furthermore, overexpression of DNMT1 and DNMT3A was as-
sociated with high-methylation tumors. These findings indi-
cate that DNMTs proteins have important roles as oncogenic 
factors and TSG methylation regulators in pituitary tumorigen-
esis and tumor progression.
It has been shown that activity of DNMT1, DNMT3A, and 
DNMT3B is increased in cancer cells and may be related to tu-
mor aggressiveness and poor prognosis [21,22,24–26]. In ad-
dition, DNMT1 protein expression was higher in the advanced 
stages of hepatocellular cancer [7]. In the present study, the 
overexpression of DNMT1 and DNMT3A was significantly related 
to tumor invasion and tumor grade. Overexpression of DNMT1 
and DNMT3A was more frequently detected in invasive adeno-
mas than in non-invasive adenomas and in was more frequent 
in grade III and IV tumors than in grade I tumors. DNMTs may 
contribute to cancer progression by silencing invasion-related 
TSGs such as CDH1, CDH13, and RASSF1A. This study and our 
previous studies [10,11] suggest that promoter methylation 
of CDH1, CDH13, and RASSF1A is associated with tumor ag-
gressiveness in pituitary adenomas. However, the exact mech-
anisms behind these associations remain to be elucidated.
Hypermethylation of gene promoter regions has been report-
ed in several TSGs, including CDKN2A, RB1, DAPK, GADD45, 
RASSF1A, CDH1, CDH13, IKAROS, FGFR2, and GSTP1 in pitu-
itary adenomas [5–14]. In addition, the association between 
expression of DNMT1 and DNMT3B and epigenetic control of 
genes has been identified in pituitary cells [19,32]. Studies of 
the relationship between the expression levels of DNMTs and 
aberrant methylation of CpG islands of genes have produced 
contradictory results in a variety of tumors. In the present 
study, DNMT1 and DNMT3A overexpression was associated 
with high-methylation status independent of other clinical 
variables, including age, sex, and tumor grade. Although ex-
pression of DNMT3B itself did not show an association with 
high-methylation status, tumors with multiple DNMTs over-
expression were associated with high-methylation status. Our 
findings are the first to demonstrate the clinical significance of 
the DNMTs/methylation connection in human pituitary tumors.
Many previous studies have been designed to examine the as-
sociation between individual DNMT expression and promot-
er methylation of individual TSG or multiple TSGs [21,35–40]. 
Although these studies produced contradictory results, it is 
clear that DNMTs overexpression was associated with multiple 
TSGs methylation status. DNMT3B was reported to be associ-
ated with the CpG island methylator high-phenotype status in 
colorectal cancers; however, in multivariate logistic regression 
analysis, DNMT3B expression remained significantly associat-
ed with just 3 TSGs promoter methylation out of 17 TSGs [37]. 
In the present study, although the number of TSGs analyzed 
was limited, DNMT1 and DNMT3A overexpression was asso-
ciated with high-methylation status in multivariate analysis 
independently of clinicopathological features. Furthermore, 
high-methylation status was frequently detected in tumors 
with overexpression of multiple DNMTs. Therefore, the above 
findings demonstrate that DNMTs expression contributes to 
high-methylation status rather than individual TSG methylation.
Pituitary adenomas are usually benign tumors of the nervous 
system. In clinic practice, some pituitary adenomas are inva-
sive and can invade surrounding structures, including the sad-
dle area, the cavernous sinus, and even the brain [2,41–43]. 
The invasiveness of pituitary adenoma is regarded as the big-
gest obstacle to the control of long-term tumor disease because 
it can limit surgical resection and lead to tumor regrowth [2]. 
Thus, it is essential to develop new adjuvant treatment for pa-
tients with aggressive pituitary tumors. While genetic muta-
tions are irreversible, epigenetic modifications are reversible. 
Therefore, epigenetic modifications are considered to be very 
attractive targets in developing new therapeutic approaches 
[29,44,45]. Hypermethylated gene promoters have the potential 
to be reactivated by nucleoside analogues such as 5-azacyti-
dine and 5-aza-2-deoxycytidine (decitabine) [46]. Azacytidine 
and decitabine are currently in use to treat myelodysplastic syn-
drome and acute myeloid leukemia [28]. In addition, a number 
of non–nucleoside analogue DNMT inhibitors such as hydrala-
zine have also been proposed as epigenetic–targeted drugs [47]. 
Furthermore, clinical trials for decitabine as treatment for solid 
tumors are already in the early stages [28]. Our data suggest 
that pituitary adenomas displaying overexpression of DNMT1 
and DNMT3A would be good candidates for epigenetic ther-
apy. In addition, as overexpression of DNMT1 and DNMT3A 
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was significantly associated with invasiveness, clinical trials for 
decitabine in invasive pituitary adenomas are recommended.
Conclusions
Our study profiled the expression status of DNMT1, DNMT3A, 
and DNMT3B in pituitary adenomas and indicated that tumoral 
overexpression of DNMT1 and DNMT3A is associated with tu-
mor aggressiveness and high-methylation status in pituitary 
adenomas. Our data demonstrated a possible role of DNMT1 
and DNMT3A in TSG promoter methylation leading to pitu-
itary adenoma invasion. Inhibition of DNMTs has the poten-
tial to become a new therapeutic approach for invasive pitu-
itary adenoma.
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